Avian influenza H5 viruses, including H5N1 and H5N6 subtypes, pose a significant global health threat with high pathogenicity in poultry and sporadic human infections. These viruses continue to evolve, raising concerns about potential pandemic transmission. The hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins are key targets for neutralizing antibodies and vaccine development, while the highly conserved M2e (matrix protein 2 ectodomain) is a promising universal vaccine candidate. Research on H5 viruses is critical for surveillance, antiviral drug development, and pandemic preparedness.

AntibodySystem offers a comprehensive portfolio of recombinant proteins and antibodies targeting avian influenza H5 subtypes (H5N1 and H5N6). Our products include HA, NA, and M2e recombinant proteins with various fusion tags (N-His, C-His, C-6His, N-GST, and carrier-fused constructs), as well as monoclonal and polyclonal antibodies validated for ELISA, WB, IHC, and other immunoassays. These reagents support avian influenza surveillance, vaccine development, and antiviral research.